World Market for Prescription Cardiovascular Drugs, 2nd Edition, The

World Market for Prescription Cardiovascular Drugs, 2nd Edition, The

As one of the most competitive pharmaceutical markets, keeping track of the cardiovascular drug market can be a difficult undertaking. The range of therapeutic options available to physicians has expanded significantly in the past few years, and will continue to increase with a robust pipeline.

Kalorama's 2nd edition of The World Market for Cardiovascular Drugs Market is designed to steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments.

Analyst Mary Ann Crandall considers both the exisitng products and the pipeline in this comprehensive market study. The following market segments are covered:

• Cardiac Glycosides and Positive Inotropic Agents


• Antihypertensive Agents (ACE Inhibitors, Angiotensin II Receptor Antagonists, Adrenergic Blockers, Beta Blockers, Calcium Channel Blockers, Combinations)


• Antiarrhythmic Agents (Class I, Class II, Class III)


• Vasodilators and Peripheral Vasodilator Agents


• Antihyperlipidemic Agents (Bile Acid Sequestrants, Fibric Acid Derivatives, Statins, Nicotonic Acid)


• Blood Modifiers (Anticoagulants, Antiplatelets, Thrmbolytics)


• Diuretic Agents (Carbonic Anhydrase Inhibitors, Loop, Potassium-Sparing, Thiazides)


• Other Cardiovascular Agents

Specific diseases and disorders discussed include:

• Angina


• Arrhythmia


• Atherosclerosis


• Congestive heart failure


• Coronary artery disease


• Hypertension


• Myocardial infarction


• Other disorders

The report details the various categories of cardiovascular drugs and describes U.S. and non-U.S. markets in each of the specific cardiovascular drug areas. Revenues are considered in each subsegment according to type of drug. In addition, top products in each category are reviewed. The report also covers market drivers and trends that are influencing the market, including:

• Obesity Epidemic and Heart Disease


• Statin use


• Inflammation Reduction


• Unique Drug Combinations


• Hormone Therapy and Cardiovascular Disease Risks


• CAD Risk Factor Differences in Sexes


• Women and Heart Disease


• OTC Statins


• Genetic Research and Wafarin Use


• Future Trends in the Pharmaceutical Arena

The report further identifies major market factors, which are discussed in detail, and a total market summary is presented.

All market data are presented at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2004. Historical data are provided for 2002 and 2003, and forecast data are provided for each of the years 2005 through 2009. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2004 base year.

As part of Kalorama's trusted information-gathering process, information and analysis presented in this report are based on extensive interviews with senior management of top companies and other participants in the cardiovascular market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals.

Key information from published literature was used to conduct interviews with over 41 industry executives and product managers to validate and obtain expert opinion on current and future trends in the cardiovascular market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
Overview of the Cardiovascular System
Heart
Circulatory System
Cardiac Cycle
Isovolumic Contraction
Ventricular Ejection
Isovolumic Relaxation
Coronary Circulation
Cardiac Myocytes
Contraction
Calcium Role in Contraction
Relaxation
Cardiac Energy Metabolism
Cardiac Output
Cardiovascular Disorders
Angina
Incidence
Etiology and Pathophysiology
Risk Factors
Arrhythmias
Incidence
Etiology and Pathophysiology
Risk Factors
Atherosclerosis
Incidence
Etiology and Pathophysiology
Risk Factors
Congestive Heart Failure
Incidence
Etiology and Pathophysiology
Risk Factors
Coronary Artery Disease
Incidence
Etiology and Pathophysiology
Risk Factors
Hypertension
Incidence
Etiology and Pathophysiology
Risk Factors
Myocardial Infarction
Incidence
Etiology and Pathophysiology
Risk Factors
Effects of Aging
Demographics
Disease Management
CHAPTER THREE: ISSUES AND TRENDS
Obesity Epidemic and Heart Disease
Statin use
Inflammation Reduction
Unique Drug Combinations
Hormone Therapy and Cardiovascular Disease Risks
CAD Risk Factor Differences in Sexes
Women and Heart Disease
Otc Statins
Genetic Research and Warfarin Use
Future Trends in the Pharmaceutical Arena
CHAPTER FOUR: PRESCRIPTION CARDIAC GLYCOSIDE AND IONTROPIC DRUGS
Overview of Cardiac Glycosides and Inotropic Drugs
Description of Products
Market Size and Growth World Market
Research and Development
Competitive Analysis
CHAPTER FIVE: PRESCRIPTION ANTIHYPERTENSIVE DRUGS
Overview
Description of Products
ACE Inhibitors
Angiotensin II Receptor Antagonists
Adrenergic Blockers
Beta Blockers
Recent Additions
Calcium Channel Blockers
Combinations
New Developments
Market Size and Growth
World Market
Research and Development
Nebivolol
CS- 8663
Volibris
Atacand Plus
Clevidipine
Coreg CR Plus ACE Inhibitor
Darusentan
Competitive Analysis
CHAPTER SIX: PRESCRIPTION ANTIARRHYTHMIC DRUGS
Overview
Description of Products
Class I
Class II
Class III
Market Size and Growth
World Market
Research and Development
Tedasamil (Pulzium)
RSD 1235 (vernakalant)
Apixaban
Bay 59-7939
Dronedarone (Multaq)
Idraparinux
Tecadenoson
Competitive Analysis
CHAPTER SEVEN: VASODILATOR AND PERIPHERAL VASODILATOR DRUGS
Overview
Description of Products
Coronary Vasodilators
Natriuretic Peptides
Peripheral Vasodilators
Recent Developments
Market Size and Growth
World Market
Research and Development
BiDil
GeneRx
Competitive Analysis
CHAPTER EIGHT: PRESCRIPTION ANTIHYPERLIPIDEMIC DRUGS
Overview
Description of Products
Bile Acid Sequestrants
Fibric Acid Derivatives
HMG-CoA Reductase Inhibitors (Statins)
Nicotinic Acid
Market Size and Growth
World Market
Research and Development
LCP-FenoChol
Synordia
Acomplia
Actos
MK 0524A, MK0524B
Pravastatin and Fenofibrate Combination
AGI-`067
ABT-335
Apo-I Milano (ETC-216)
ETC-642
FM-VP4
Competitive Analysis
CHAPTER NINE: PRESCRIPTION BLOOD MODIFIER DRUGS
Overview
Description of Products
Anticoagulants
Antiplatelets
Thrombolytics
New Developments
Market Size and Growth
World Market
Research and Development
Arixtra
Exanta
Cangrelor
(Prasugrel) CS-747
Integrilin
Competitive Analysis
CHAPTER TEN: PRESCRIPTION DIURETIC DRUGS
Overview
Description of Products
Carbonic Anhydrase Inhibitors
Loop
Potassium-Sparing
Thiazides
Market Size and Growth
World Market
Research and Development
Competitive Analysis
CHAPTER ELEVEN: PRESCRIPTION OTHER CARDIOVASCULAR DRUGS
Overview
Description of Products
Market Size and Growth
World Market
Research and Development
Thelin
Remodulin IV
Ambrisentan (Letairis)
Celacade
Tadalafil
Tolvaptan
DITPA
Competitive Analysis
CHAPTER TWELVE: WORLD MARKET SUMMARY
Overview
Total Market Size and Forecast
Competitor Analysis
CHAPTER THIRTEEN: CORPORATE PROFILES
Abbott Laboratories
AStellas Pharma, Inc.
Astra Zeneca
Bayer Schering Pharma
Biovail Corporation
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Pharmaceuticals
Eli Lilly and Company
Genentech, Inc.
GlaxoSmithKline
MERCK & COMPANY INC
Novartis International AG
Pfizer, Inc.
Roche
Sanofi-Aventis
Takeda Pharmaceuticals
Emerging Cardiovascular Companies
Cardiome Pharma Corporation
Inotek Pharmaceuticals Corporation
APPENDIX: COMPANY DIRECTORY
TABLE OF EXHIBITS
EXECUTIVE SUMMARY
Table 1-1: Total World Prescription Cardiovascular Drug Market 2004-2011
Figure 1-1: Total World Prescription Cardiovascular Drug Market 2004-2011
Table1-2: World Market for Prescription
Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2006
Figure 1-2: World Market for Prescription Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2006
CHAPTER TWO: INTRODUCTION
Table 2-1: U.S. Prevalence, Incidence and Mortality of Selected Cardiovascular Conditions
CHAPTER FOUR: PRESCRIPTION CARDIAC GLYCOSIDE AND IONTROPIC DRUGS
Table 4-1: Marketed Cardiac Glycosides and Inotropic Drugs
Table 4-2: Total World Cardiac Glycoside & Inotropic Drug Market 2004-2011
Figure 4-1: Total World Cardiac Glycoside & Inotropic Drug Market 2004-2011
Table 4-3: Cardiac Glycosides and Inotropic Agents in Development
Table 4-4: Total Global Market for Cardiac Glycoside & Inotropic Drugs, Revenues and Market Share by Supplier 2006
Figure 4-2: Total Global Market for Cardiac Glycoside & Inotropic Drugs, Market Share by Leading Supplier 2006
CHAPTER FIVE: PRESCRIPTION ANTIHYPERTENSIVE DRUGS
Table 5-1: Marketed ACE Inhibitors
Table 5-2: Marketed Angiotensin II Receptor Antagonists
Table 5-3: Marketed Adrenergic and Beta Blockers
Table 5-4: Marketed Calcium Channel Blockers
Table 5-5: Marketed Combination and Other Antihypertensives
Table 5-6: Total World Prescription Antihypertensive Drug Market 2004-2011
Figure 5-1: Total World Prescription Antihypertensive Drug Market 2004-2011
Table 5-6: Total World Prescription Antihypertensive Drug Market by Type 2004-2011
Figure 5-2: Total World Prescription Antihypertensive Drug Market by Type 2006
Table 5-7: Hypertensive Drugs in Development
Table 5-8: Total Global Market for Prescription Antihypertensive Drugs, Revenues and Market Share by Supplier 2006
Figure 5-9: Total Global Market for Prescription Antihypertensive Drugs, Market Share by Leading Supplier 2006
CHAPTER SIX: PRESCRIPTION ANTIARRHYTHMIC DRUGS
Table 6-1: Marketed Antiarrhythmic Drugs
Table 6-2: Total World Prescription Antiarrhythmic Drug Market 2004-2011
Figure 6-1: Total World Prescription Antiarrhythmic Drug Market 2004-2011
Table 6-3: Antiarrhythmic Drugs in Development
Table 6-4: Total Global Market for Prescription Antiarrhythmic Drugs, Revenues and Market Share by Supplier 2006
Figure 6-3: Total Global Market for Prescription Antiarrhythmic Drugs, Market Share by Leading Supplier 2006
CHAPTER SEVEN: VASODILATOR AND PERIPHERAL VASODILATOR DRUGS
Table 7-1: Marketed Vasodilator and Peripheral Vasodilator Drugs
Table 7-2: Total World Vasodilator and Peripheral Vasodilator Drugs Market 2004-2011
Figure 7-2: Total World Vasodilator and Peripheral Vasodilator Drugs Market 2004-2011
Table 7-3: Vasodilator and Peripheral Vasodilator Drugs in Development
Table 7-4: Total Global Market for Vasodilator and Peripheral Vasodilator Drugs Revenues and Market Share by Supplier 2006
Figure 7-4: Total Global Market for Vasodilator and Peripheral Vasodilator Drugs Market Share by Leading Supplier 2006
CHAPTER EIGHT: PRESCRIPTION ANTIHYPERLIPIDEMIC DRUGS
Table 8-1: Marketed Antihyperlipidemic Drugs
Table 8-2: Total World Prescription Antihyperlipidemic Drugs Market 2004-2011
Figure 8-1: Total World Prescription Antihyperlipidemic Drugs Market 2004-2011
Table 8-3: Antihyperlipidemic Drugs in Development
Table 8-4: Total Global Market for Prescription Antihyperlipidemic Drugs Revenues and Market Share by Supplier 2006
Figure 8-2: Total Global Market for Prescription Antihyperlipidemic Drugs Market Share by Leading Supplier 2006
CHAPTER NINE: PRESCRIPTION BLOOD MODIFIER DRUGS
Table 9-2: Marketed Anticoagulant Drugs
Table 9-3: Marketed Antiplatelet Drugs
Table 9-4: Marketed Thrombolytic Drugs
Table 9-5: Total World Prescription Blood Modifier Drug Market 2004-2011
Figure 9-1: Total World Prescription Blood Modifier Drug Market 2004-2011
Table 9-6: The Global Market for Prescription Blood Modifier Drugs by Type 2004-2011
Figure 9-2: Global Market for Prescription Blood Modifier Drugs by Type 2006
Table 9-7: Blood Modifier Drugs in Development
Table 9-8: Total Global Market for Prescription Blood Modifiers, Revenues and Market Share by Supplier 2006
Figure 9-4: Total Global Market for Prescription Blood Modifier Drugs, Market Share by Leading Supplier 2006
CHAPTER TEN: PRESCRIPTION DIURETIC DRUGS
Table 10-1: Marketed Diurectic Drugs
Table 10-2: Total World Prescription Diuretic Drugs Market 2004-2011
Figure 10-1: Total World Prescription Diuretic Drugs Market 2004-2011
Table 10-3: Diuretic Drugs in Development
Table 10-4: Total Global Market for Prescription Diuretic Drugs, Revenues and Market Share by Supplier 2006
Figure 10-2: Total Global Market for Prescription Diuretic Drugs, Market Share by Leading Supplier 2006
CHAPTER ELEVEN: PRESCRIPTION OTHER CARDIOVASCULAR DRUGS
Table 11-1: Marketed Other Cardiovascular Drugs
Table 11-2: Total World Other Cardiovascular Drug Market 2004-2011
Figure 11-1: Total World Other Cardiovascular Drug Market 2004-2011
Table 11-3: Other Cardiovascular Drugs in Development
Table 11-4: Total World Market for Other Cardiovascular Drugs Revenues and Market Share by Supplier 2006
Figure 11-5: Total World Market for Other Cardiovascular Drugs Market Share by Leading Supplier 2006
CHAPTER TWELVE: WORLD MARKET SUMMARY
Table 12-1: Total World Prescription Cardiovascular Drug Market 2004-2011
Table 12-2 Total World Prescription Cardiovascular Drug Market by Product Segment 2004-2011
Figure 12-1: Total World Prescription Cardiovascular Drug Market by Product Segment 2004-2011
Figure 12-2: The World Market for Prescription Cardiovascular Drugs by Product Segment Market Share 2006
Table 12-3: World Market for Prescription Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2006
Figure 12-3: World Market for Prescription Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2006